Akari Therapeutics, Plc
AKTX
$1.40
-$0.03-2.10%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 10.71M | 10.24M | 11.35M | 12.20M | 11.36M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.69M | 18.49M | 19.14M | 18.20M | 16.81M |
| Operating Income | -17.69M | -18.49M | -19.14M | -18.20M | -16.81M |
| Income Before Tax | -19.79M | -20.16M | -20.13M | -16.58M | -10.01M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.79 | -20.16 | -20.13 | -16.58 | -10.01 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.79M | -20.16M | -20.13M | -16.58M | -10.01M |
| EBIT | -17.69M | -18.49M | -19.14M | -18.20M | -16.81M |
| EBITDA | -17.68M | -18.47M | -19.13M | -18.19M | -16.80M |
| EPS Basic | -4.12K | -5.62K | -6.28K | -6.25K | -4.06K |
| Normalized Basic EPS | -1.08 | -1.57 | -1.84 | -1.95 | -1.27 |
| EPS Diluted | -4.12K | -5.62K | -6.28K | -6.25K | -4.07K |
| Normalized Diluted EPS | -1.08 | -1.57 | -1.84 | -1.95 | -1.27 |
| Average Basic Shares Outstanding | 47.75M | 32.74M | 25.60M | 21.24M | 18.25M |
| Average Diluted Shares Outstanding | 23.70K | 16.10K | 12.60K | 10.40K | 8.90K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |